¥
DAPAGLIFLOZIN FOR PATIENTS WITH TYPE 2 DIABETES
KICKSTART THE CHANGE^
YOU
^
WANT TO SEE1 – 4
SIGNIFICANT ¶
HbA 1c REDUCTION
SUSTAINED OUT TO 102 WEEKS WHEN ADDED TO METFORMIN IR, COMPARED TO PLACEBO PLUS METFORMIN IR. 1 – 4
¶ Statistically significant; P < 0.0001.
WEIGHT LOSS † 1 – 4
AT 102 WEEKS, COMPARED WITH PLACEBO, IN PATIENTS TAKING METFORMIN IR. † Dapagliflozin is not indicated for weight loss. Secondary endpoint. 1 – 4
DAPAGLIFLOZIN WITH THE ADDITIONAL BENEFITS OF:
SYSTOLIC BLOOD PRESSURE REDUCTION ‡# 5, 6
ON TOP OF BACKGROUND ANTIHYPERTENSIVE THERAPY § AT 12 WEEKS, COMPARED TO PLACEBO. 5, 6
‡ Dapagliflozin is not indicated for blood pressure reduction. Co-primary endpoint with change in HbA1c. 5, 6
# No significant difference in DBP between groups. 5, 6
§ ARB / ACEi with or without one additional antihypertensive agent.
( dapagliflozin( dapagliflozin))( dapagliflozin / / metformin HCl extended-release HCl) tablets
XIGDUO ® XR( dapagliflozin / metformin XR) is bioequivalent to co-administration of approved doses of individual components. 2 Comparable glycaemic control has been shown between metformin immediate( IR) and extended-release( XR) formulations. 7
BEFORE PRESCRIBING, PLEASE REVIEW PBS AND PRODUCT INFORMATION AVAILABLE IN THE PRIMARY ADVERTISEMENT IN THIS PUBLICATION OR ON REQUEST FROM ASTRAZENECA.
References: 1. FORXIGA ® Approved Product Information. 2. XIGDUO ® XR Approved Product Information. 3. Bailey CJ et al. Lancet 2010; 375:2223 – 2233. 4. Bailey CJ et al. BMC Medicine 2013; 11; 43:1 – 10. 5. Weber MA et al. Lancet Diab Endocrinol 2016; 4:211 – 220. 6. Weber MA et al. Blood Pressure 2015; 25:93 – 103. 7. Fujioka K et al. Clinical Therapeutics 2003; 25( 2): 515 – 529. DBP = diastolic blood pressure; HbA 1c = haemoglobin A 1c; IR = immediate release; XR = extended release; ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker. FORXIGA ® and XIGDUO ® XR are registered trademarks of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. AstraZeneca Medical Information: 1800 805 342. January 2017. AU-1659. 14014.